Amicus Therapeutics is growing steadily with Galafold and a promising Pompe therapy, targeting $1B revenue by 2028. See why ...

The drug licensing talks cover the development, production and sale of a targeted cancer therapy and other CSPC Pharma ...

PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository ...

Gross domestic product (GDP) measures the value of goods and services produced in the UK. It estimates the size of and growth in the economy. Monthly real gross domestic product (GDP) is estimated to ...

The Bangladesh Association of Pharmaceuticals Industries (BAPI) views the proposed extension and enhancement of duty and tax exemptions on the import of raw materials for the pharmaceutical sector in ...

“To date, the available procedural pharmaceuticals use PGAs,” the study authors ... and to have featured objective measures of compliance. Given these high rates of attrition, alternative therapeutic ...

TCS Attrition Rate in Q4 Results Data: The company has released its quarterly earnings for Q4 FY25 on Thursday. (Image: Reuters) TCS Attrition Rate Data After Q4 Results: Tata Consultancy Services ...

The performance benchmark of the Science and Technology Innovation Pharmaceutical Index ETF (588700) is the return rate of the SSE Science and Technology ... In terms of liquidity, as of April 7, the ...

Getty Images/iStockphoto North Carolina’s teacher turnover rate has dropped 14% but still remains higher than it’s been in recent years, according to the newest state report. The report ...

tech advancements and high attrition rates; the pharma cohort spent $7.7 billion on trials for candidates that were terminated in 2024, according to the analysis. While R&D costs are up ...

With the global economy facing turbulent times, companies and employees have both become more cautious. A new report has highlighted that employee attrition in India Inc declined in 2024 as ...